Clinical Trials Logo

Drug Resistant clinical trials

View clinical trials related to Drug Resistant.

Filter by:
  • None
  • Page 1

NCT ID: NCT05198882 Recruiting - Epilepsy Clinical Trials

Clinical Evaluation of Interstitial Laser Thermal Therapy Under Continuous MRI Monitoring as a Minimally Invasive Treatment of Patients With Medically Unbalanced Partial Epilepsy

EPILITT
Start date: July 4, 2022
Phase: Phase 1
Study type: Interventional

Laser Induced Interstitial Thermal Therapy (LITT) is a "minimally invasive" procedure that uses the heat generated by a laser light (65°) to destroy brain lesions by coagulation leading to lesion necrosis under real-time MRI monitoring. The laser optical fiber is implanted into the lesion using stereotaxy. This technique, which can be performed under local anesthesia and on an outpatient basis, proved its efficacy and safety in the treatment of brain metastases for the first time in the world in 2006 (A. Carpentier et al, 2008, 2011). Since then, more than 5,000 patients have been treated in the USA, including for epileptogenic lesions (FDA device and CE cleared). Our goal is to evaluate LITT on lesions with drug-resistant epilepsy for which surgical resection is impossible. No therapeutic trial evaluating LITT in this indication has been performed to date. It is therefore necessary to study its feasibility and tolerance.

NCT ID: NCT04544215 Recruiting - Drug-resistant Clinical Trials

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection

Start date: July 1, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the efficacy and safety of haMPC-Exos treatment with pulmonary infection caused by gram-negative bacilli resistant to carbapenems.

NCT ID: NCT00376766 Terminated - Epilepsy Clinical Trials

Clinical Trial : TROCC (Quick Oral Treatment of Cluster Epileptic Seizures)

Start date: February 2007
Phase: Phase 3
Study type: Interventional

This is a double blind, placebo controlled, add-on clinical trial, of levetiracetam efficacy and safety, in epilepsy cluster seizure. Efficacy is evaluated in the range of 2 to 24 hours after taking the tablet. If the patient has a seizure during this interval, he is considered as a non-respondent patient.

NCT ID: NCT00228371 Terminated - Epilepsy Clinical Trials

STIMEP : Assessment of Subthalamic Nucleus Stimulation in Drug Resistant Epilepsy

Start date: September 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to evaluate the effectiveness and the safety of deep brain stimulation in drug resistant epilepsy. This is a double blind, controlled and randomized clinical trial with two cross-over groups and four phases. Phase 1 : base line, open phase consisting of follow-up of patients with their standard treatment. Phase 2 : Randomisation, lead implantation, followed by 3 months wash out period with the stimulator switch OFF. Phase 3 : cross-over, double blind phase : 3 months with stimulator switch ON or OFF depending on randomization allocation, followed by 3 months with the stimulator switch on the opposite position. The placebo consisting of turn OFF the stimulator. Phase 4 : open phase, one year follow-up of all patients with the stimulator switch ON.